CD8A and cancer: The capsid‐engineered AAV vector‐based vaccine, with genetic insertion of major histocompatibility complex Class I/II (MHC Class I/II), could induce robust and long‐lasting antigen‐specific humoral and CD4+ and CD8+ T cell immune responses after single intramuscular administration, serving as a novel vaccine platform for cancer immunotherapy [310].